Therapeutic effects of renal denervation on renal failure

Current Neurovascular Research

Volumn 10, Issue 2, 2013, Pages 172-184

  Wang, Yutang ^a   Seto, Sai Wang ^a   Golledge, Jonathan ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Acute kidney injury; Chronic kidney disease; Re innervation; Renal denervation; Sympathetic nerve activity

Indexed keywords

CARVEDILOL; METOPROLOL; MOXONIDINE; PHENOXYBENZAMINE;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONGESTIVE CARDIOMYOPATHY; EFFERENT NERVE; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY NERVE; LOW DRUG DOSE; MICROALBUMINURIA; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHIZOTOMY; SENSORY NERVE; SYMPATHETIC NERVE;

EID: 84879809921     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202611310020010     Document Type: Review

References (113)

1. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-212.
2. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17-28.
3. Parikh A, Shaw A. The economics of renal failure and kidney disease in critically ill patients. Crit Care Clin 2012;28:99-111, vii.
4. Brown RO, Compher C. A.S.P.E.N. clinical guidelines: nutrition support in adult acute and chronic renal failure. JPEN J Parenter Enteral Nutr 2010;34:366-377.
5. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-3370.
6. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-1979.
7. Converse RL, Jr., Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918.
8. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-1328.
9. McGrath BP, Ledingham JG, Benedict CR. Catecholamines in peripheral venous plasma in patients on chronic haemodialysis. Clin Sci Mol Med 1978;55:89-96.
10. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011;57:846-851.
11. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003;21:1709-1717.
12. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-2433.
13. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003;14:3239-3244.
14. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 2008;105:1873-1876.
15. Grassi G, Seravalle G, Arenare F, et al. Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. J Hypertens 2009;27:562-566.
16. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-1359.
17. Getts RT, Hazlett SM, Sharma SB, et al. Regression of left ventricular hypertrophy after bilateral nephrectomy. Nephrol Dial Transplant 2006;21:1089-1091.
18. Wang W, Falk SA, Jittikanont S, Gengaro PE, Edelstein CL, Schrier RW. Protective effect of renal denervation on normotensive endotoxemia-induced acute renal failure in mice. Am J Physiol Renal Physiol 2002;283:F583-587.
19. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000;11:1469-1478.
20. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001;60:1309-1323.
21. Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001;12:602-605.
22. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat Am J Kidney Dis 1995;26:861-865.
23. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-1444.
24. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009;20:933-939.
25. Neumann J, Ligtenberg G, Klein, II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004;65:1568-1576.
26. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004;43:699-706.
27. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004;15:435-441.
28. Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther 2006;23:988-998.
29. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol 1983;245:F1-14.
30. Katholi RE, Rocha-Singh KJ. The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance? Prog Cardiovasc Dis 2009;52:243-248.
31. Moss NG. Renal function and renal afferent and efferent nerve activity. Am J Physiol 1982;243:F425-433.
32. Schrier RW. Effects of adrenergic nervous system and catecholamines on systemic and renal hemodynamics, sodium and water excretion and renin secretion. Kidney Int 1974;6:291-306.
33. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75-197.
34. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002;11:197-200.
35. Kopp UC, Cicha MZ, Smith LA, Mulder J, Hokfelt T. Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1-and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 2007;293:R1561-1572.
36. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002;15:717-724.
37. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev 1991;71:659-682.
38. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997;51:722-727.
39. Miyajima E, Yamada Y, Yoshida Y, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991;17:1057-1062.
40. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998;11:723-728.
41. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009;54:1195-1201.
42. Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004;43:169-175.
43. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007;115:1999-2005.
44. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009;361:932-934.
45. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
46. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-1909.
47. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension Symplicity HTN-1 Investigators, 2011;57:911-917.
48. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-1946.
49. Henrich WL, Hamasaki Y, Said SI, Campbell WB, Cronin RE. Dissociation of systemic and renal effects in endotoxemia. Prostaglandin inhibition uncovers an important role of renal nerves. J Clin Invest 1982;69:691-699.
50. Salman IM, Ameer OZ, Sattar MA, et al. Characterization of renal hemodynamic and structural alterations in rat models of renal impairment: role of renal sympathoexcitation. J Nephrol 2011;24:68-77.
51. Nakashima A, Matsuoka H, Yasukawa H, et al. Renal denervation prevents intraglomerular platelet aggregation and glomerular injury induced by chronic inhibition of nitric oxide synthesis. Nephron 1996;73:34-40.
52. Kelleher SP, Robinette JB, Miller F, Conger JD. Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure. Kidney Int 1987;31:725-730.
53. Kelleher SP, Robinette JB, Conger JD. Sympathetic nervous system in the loss of autoregulation in acute renal failure. Am J Physiol 1984;246:F379-386.
54. Conger JD. Vascular abnormalities in the maintenance of acute renal failure. Circ Shock 1983;11:235-244.
55. Robinette JB, Conger JD. Angiotensin and thromboxane in the enhanced renal adrenergic nerve sensitivity of acute renal failure. J Clin Invest 1990;86:1532-1539.
56. Bidani A, Al-Hawasli A, Churchill P. The effect of denervation diuresis on the severity of glycerol-induced acute renal failure in rats. J Lab Clin Med 1983;102:1000-1009.
57. Fujii T, Kurata H, Takaoka M, et al. The role of renal sympathetic nervous system in the pathogenesis of ischemic acute renal failure. Eur J Pharmacol 2003;481:241-248.
58. Salman IM, Ameer OZ, Sattar MA, et al. Role of the renal sympathetic nervous system in mediating renal ischaemic injury-induced reductions in renal haemodynamic and excretory functions. Pathology 2010;42:259-266.
59. Ogawa T, Mimura Y, Kaminishi M. Renal denervation abolishes the protective effects of ischaemic preconditioning on function and haemodynamics in ischaemia-reperfused rat kidneys. Acta Physiol Scand 2002;174:291-297.
60. Amann K, Odoni G, Benz K, et al. Sympathetic blockade prevents the decrease in cardiac VEGF expression and capillary supply in experimental renal failure. Am J Physiol Renal Physiol 2011;300:F105-112.
61. Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR. Cigarette smoke condensate aggravates renal injury in the renal ablation model. Kidney Int 2002;61:2090-2098.
62. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878-882.
63. O'Neill PA, Wait RB, Kahng KU. Role of renal sympathetic nerve activity in renal failure associated with obstructive jaundice in the rat Am J Surg 1991;161:662-667.
64. Chaimovitz C, Massry SG, Friedler RM, Coburn JW. Effect of renal denervation and alpha-adrenergic blockade on sodium excretion in dogs with chronic ligation of the common bile duct. Proc Soc Exp Biol Med 1974;146:764-770.
65. Li WJ, Bergman SM, Holmes RP, Strandhoy JW, Handa RK, McCullough DL. Tetrodotoxin protects against acute ischemic renal failure in the rat. J Urol 1992;147:519-522.
66. Solez K, D'Agostini RJ, Stawowy L, et al. Beneficial effect of propranolol in a histologically appropriate model of postischemic acute renal failure. Am J Pathol 1977;88:163-192.
67. Wyss JM, Donovan MK. A direct projection from the kidney to the brainstem. Brain Res 1984;298:130-134.
68. Streitparth F, Walter A, Stolzenburg N, et al. MR-guided Periarterial Ethanol Injection for Renal Sympathetic Denervation: A Feasibility Study in Pigs. Cardiovasc Intervent Radiol 2013 (in press).
69. Cronin RE, Erickson AM, de Torrente A, McDonald KM, Schrier RW. Norepinephrine-induced acute renal failure: a reversible ischemic model of acute renal failure. Kidney Int 1978;14:187-190.
70. Adams PL, Adams FF, Bell PD, Navar LG. Impaired renal blood flow autoregulation in ischemic acute renal failure. Kidney Int 1980;18:68-76.
71. Matthys E, Patton MK, Osgood RW, Venkatachalam MA, Stein JH. Alterations in vascular function and morphology in acute ischemic renal failure. Kidney Int 1983;23:717-724.
72. Chevalier RL, Finn WF. Effects of propranolol on post-ischemic acute renal failure. Nephron 1980;25:77-81.
73. Ott C, Schmid A, Ditting T, et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens (Greenwich) 2012;14:799-801.
74. Di Daniele N, De Francesco M, Violo L, Spinelli A, Simonetti G. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol Dial Transplant 2012;27:1689-1690.
75. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012;23:1250-1257.
76. Lewalter T, Brodherr T. Three-dimensional guided renal denervation to treat drug-resistant arterial hypertension in a patient with renal insufficiency. Hypertension 2012;60:e33.
77. Ormiston JA, Watson T, van Pelt N, et al. First-in-human use of the OneShot renal denervation system from Covidien. EuroIntervention 2013;8:1090-1094.
78. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011;58:559-565.
79. Whitworth JA. Progression of renal failure-the role of hypertension. Ann Acad Med Singapore 2005;34:8-15.
80. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661.
81. Wong VY, Laping NJ, Nelson AH, et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol 2001;134:977-984.
82. Esler M, Schlaich M, Sobotka P, et al. Catheter-based renal denervation reduces total body and renal noradrenaline spillover and blood pressure in resistant hypertension. J Hypertens 2009;27 (suppl 4): S167.
83. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004;22:2363-2369.
84. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
85. Brown JJ, Gleadle RI, Lawson DH, et al. Renin and acute renal failure: studies in man. Br Med J 1970;1:253-258.
86. Mendelsohn FA, Smith EA. Intrarenal renin, angiotensin II, and plasma renin in rats with uranyl nitrate-induced and glycerol-induced acute renal failure. Kidney Int 1980;17:465-472.
87. Wagner J, Klotz S, Haufe CC, et al. Progression of renal failure after subtotal nephrectomy in transgenic rats carrying an additional renin gene [TGR(mREN2)27]. J Hypertens 1997;15:441-449.
88. el-Dahr SS, Gomez RA, Gray MS, Peach MJ, Carey RM, Chevalier RL. Renal nerves modulate renin gene expression in the developing rat kidney with ureteral obstruction. J Clin Invest 1991;87:800-810.
89. Zhang Y, Morgan T, Read G. The role of the renal nerves in renin synthesis. Clin Exp Pharmacol Physiol 1992;19:827-831.
90. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
91. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-771.
92. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
93. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet The GISEN Group, 1997;349:1857-1863.
94. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-364.
95. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
96. Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 2011;300:F31-39.
97. Pflueger A, Larson TS, Nath KA, King BF, Gross JM, Knox FG. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 2000;75:1275-1283.
98. Gould J, Bowmer CJ, Yates MS. Renal haemodynamic responses to adenosine in acute renal failure. Nephron 1995;71:184-189.
99. Ishikawa I, Shikura N, Takada K. Amelioration of glycerol-induced acute renal failure in rats by an adenosine A1 receptor antagonist (FR-113453). Ren Fail 1993;15:1-5.
100. Nagashima K, Kusaka H, Karasawa A. Protective effects of KW-3902, an adenosine A1-receptor antagonist, against cisplatin-induced acute renal failure in rats. Jpn J Pharmacol 1995;67:349-357.
101. Gould J, Morton MJ, Sivaprasadarao A, Bowmer CJ, Yates MS. Renal adenosine A1 receptor binding characteristics and mRNA levels during the development of acute renal failure in the rat. Br J Pharmacol 1997;120:947-953.
102. Suzuki F, Shimada J, Mizumoto H, et al. Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. J Med Chem 1992;35:3066-3075.
103. Yao K, Kusaka H, Sano J, Sato K, Karasawa A. Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in various models of acute renal failure in rats. Jpn J Pharmacol 1994;64:281-288.
104. Lee HT, Ota-Setlik A, Xu H, D'Agati VD, Jacobson MA, Emala CW. A3 adenosine receptor knockout mice are protected against ischemia-and myoglobinuria-induced renal failure. Am J Physiol Renal Physiol 2003;284:F267-273.
105. Kline RL, Mercer PF. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol 1980;238:R353-358.
106. Wright JT, Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431.
107. Katholi RE, Winternitz SR, Oparil S. Role of the renal nerves in the pathogenesis of one-kidney renal hypertension in the rat Hypertension 1981;3:404-409.
108. Diz DI, Nasjletti A, Baer PG. Renal denervation at weaning retards development of hypertension in New Zealand genetically hypertensive rats. Hypertension 1982;4:361-368.
109. Winternitz SR, Katholi RE, Oparil S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. J Clin Invest 1980;66:971-978.
110. Mogil RA, Itskovitz HD, Russell JH, Murphy JJ. Plasma renin activity and blood pressure before and after renal denervation. Invest Urol 1970;7:442-447.
111. Mogil RA, Itskovitz HD, Russell JH, Murphy JJ. Renal innervation and renin activity in salt metabolism and hypertension. Am J Physiol 1969;216:693-697.
112. Nomura G, Kurosaki M, Takabatake T, Kibe Y, Takeuchi J. Reinnervation and renin release after unilateral renal denervation in the dog. J Appl Physiol 1972;33:649-655.
113. Hansen JM, Abildgaard U, Fogh-Andersen N, et al. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond) 1994;87:13-20.